HealthDay News — For males, receipt of a red blood cell transfusion from an ever-pregnant female is associated with increased rate of all-cause mortality compared with a male donor, according to a study published online October 17 in the Journal of the American Medical Association.
Camila Caram-Deelder, from Sanquin Research in the Netherlands, and colleagues examined the correlation between mortality and exposure to transfusions from ever-pregnant or never-pregnant female donors in a retrospective cohort study involving 31,118 first-time transfusion recipients.
The researchers found that mortality was 13% in the cohort. All-cause mortality rates for male recipients of red blood cell transfusions from an ever-pregnant female donor versus a male donor were 101 versus 80 deaths per 1,000 person-years (time-dependent per-transfusion hazard ratio [HR] for death, 1.13; 95% confidence interval [CI], 1.01 to 1.26). Mortality rates were 78 versus 80 deaths per 1,000 person-years for male recipients of transfusion from a never-pregnant female donor versus a male donor (HR, 0.93; 95% CI, 0.81 to 1.06). For female recipients of red blood cell transfusion, mortality rates were 74 versus 62 per 1,000 person-years for an ever-pregnant female versus a male donor (HR, 0.99; 95% CI, 0.87 to 1.13) and 74 versus 62 per 1,000 person-years for a never-pregnant female versus a male donor (HR, 1.01; 95% CI, 0.88 to 1.15).
“Further research is needed to replicate these findings, determine their clinical significance, and identify the underlying mechanism,” the authors write.
One author disclosed financial ties to the pharmaceutical industry.